Tempus AI (NASDAQ:TEM) Trading 4.2% Higher – Still a Buy?

Tempus AI, Inc. (NASDAQ:TEM) shot up 4.2% during trading on Tuesday . The company traded as high as $47.23 and last traded at $47.08. 3,436,270 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 4,804,807 shares. The stock had previously closed at $45.17.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TEM shares. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Piper Sandler dropped their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Bank of America boosted their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, TD Cowen reiterated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Price Performance

The firm has a 50 day simple moving average of $54.30 and a two-hundred day simple moving average of $52.30. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Buying and Selling

In related news, Director David R. Epstein sold 620 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares of the company’s stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nadja West sold 809 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total transaction of $41,347.99. Following the sale, the director now directly owns 37,705 shares in the company, valued at approximately $1,927,102.55. The trade was a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,406,855 shares of company stock worth $350,610,637 in the last ninety days.

Hedge Funds Weigh In On Tempus AI

Large investors have recently bought and sold shares of the company. Operose Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter valued at approximately $25,000. First Horizon Advisors Inc. acquired a new position in Tempus AI in the 3rd quarter valued at approximately $30,000. Farther Finance Advisors LLC bought a new position in shares of Tempus AI during the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI in the fourth quarter valued at $49,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.